S&P 500   3,925.43 (+1.14%)
DOW   31,961.86 (+1.35%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
S&P 500   3,925.43 (+1.14%)
DOW   31,961.86 (+1.35%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
S&P 500   3,925.43 (+1.14%)
DOW   31,961.86 (+1.35%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
S&P 500   3,925.43 (+1.14%)
DOW   31,961.86 (+1.35%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
Log in
OTCMKTS:ENZN

Enzon Pharmaceuticals Competitors

$0.61
-0.04 (-5.46 %)
(As of 02/24/2021 03:53 PM ET)
Add
Compare
Today's Range
$0.60
Now: $0.61
$0.67
50-Day Range
$0.27
MA: $0.50
$0.84
52-Week Range
$0.02
Now: $0.61
$0.85
Volume79,062 shs
Average Volume448,524 shs
Market Capitalization$45.61 million
P/E RatioN/A
Dividend YieldN/A
Beta0.77

Competitors

Enzon Pharmaceuticals (OTCMKTS:ENZN) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying ENZN stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Enzon Pharmaceuticals, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Enzon Pharmaceuticals (OTCMKTS:ENZN) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.

Risk & Volatility

Enzon Pharmaceuticals has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.

Profitability

This table compares Enzon Pharmaceuticals and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Enzon Pharmaceuticals-1,711.94%-20.29%-18.69%
Amgen29.42%95.55%15.52%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Enzon Pharmaceuticals and Amgen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Enzon Pharmaceuticals0000N/A
Amgen0111402.56

Amgen has a consensus price target of $256.0909, suggesting a potential upside of 11.35%. Given Amgen's higher probable upside, analysts clearly believe Amgen is more favorable than Enzon Pharmaceuticals.

Earnings and Valuation

This table compares Enzon Pharmaceuticals and Amgen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enzon Pharmaceuticals$210,000.00217.17$-980,000.00N/AN/A
Amgen$23.36 billion5.69$7.84 billion$14.8215.52

Amgen has higher revenue and earnings than Enzon Pharmaceuticals.

Institutional & Insider Ownership

75.2% of Amgen shares are owned by institutional investors. 0.0% of Enzon Pharmaceuticals shares are owned by insiders. Comparatively, 0.4% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Amgen beats Enzon Pharmaceuticals on 9 of the 11 factors compared between the two stocks.

Enzon Pharmaceuticals (OTCMKTS:ENZN) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.

Risk & Volatility

Enzon Pharmaceuticals has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500.

Profitability

This table compares Enzon Pharmaceuticals and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Enzon Pharmaceuticals-1,711.94%-20.29%-18.69%
Gilead Sciences5.48%37.77%12.76%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Enzon Pharmaceuticals and Gilead Sciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Enzon Pharmaceuticals0000N/A
Gilead Sciences2121202.38

Gilead Sciences has a consensus price target of $96.0370, suggesting a potential upside of 50.74%. Given Gilead Sciences' higher probable upside, analysts clearly believe Gilead Sciences is more favorable than Enzon Pharmaceuticals.

Earnings and Valuation

This table compares Enzon Pharmaceuticals and Gilead Sciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enzon Pharmaceuticals$210,000.00217.17$-980,000.00N/AN/A
Gilead Sciences$22.45 billion3.56$5.39 billion$6.1410.38

Gilead Sciences has higher revenue and earnings than Enzon Pharmaceuticals.

Institutional & Insider Ownership

76.4% of Gilead Sciences shares are owned by institutional investors. 0.0% of Enzon Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Gilead Sciences beats Enzon Pharmaceuticals on 9 of the 11 factors compared between the two stocks.

Enzon Pharmaceuticals (OTCMKTS:ENZN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.

Risk & Volatility

Enzon Pharmaceuticals has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.

Profitability

This table compares Enzon Pharmaceuticals and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Enzon Pharmaceuticals-1,711.94%-20.29%-18.69%
Vertex Pharmaceuticals38.51%28.55%20.68%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Enzon Pharmaceuticals and Vertex Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Enzon Pharmaceuticals0000N/A
Vertex Pharmaceuticals042312.89

Vertex Pharmaceuticals has a consensus price target of $291.8462, suggesting a potential upside of 34.47%. Given Vertex Pharmaceuticals' higher probable upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Enzon Pharmaceuticals.

Earnings and Valuation

This table compares Enzon Pharmaceuticals and Vertex Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enzon Pharmaceuticals$210,000.00217.17$-980,000.00N/AN/A
Vertex Pharmaceuticals$4.16 billion13.55$1.18 billion$4.2950.59

Vertex Pharmaceuticals has higher revenue and earnings than Enzon Pharmaceuticals.

Institutional & Insider Ownership

92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.0% of Enzon Pharmaceuticals shares are owned by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Vertex Pharmaceuticals beats Enzon Pharmaceuticals on 11 of the 12 factors compared between the two stocks.

Enzon Pharmaceuticals (OTCMKTS:ENZN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.

Institutional & Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 0.0% of Enzon Pharmaceuticals shares are owned by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Enzon Pharmaceuticals has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500.

Profitability

This table compares Enzon Pharmaceuticals and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Enzon Pharmaceuticals-1,711.94%-20.29%-18.69%
Regeneron Pharmaceuticals38.28%28.97%20.11%

Earnings and Valuation

This table compares Enzon Pharmaceuticals and Regeneron Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enzon Pharmaceuticals$210,000.00217.17$-980,000.00N/AN/A
Regeneron Pharmaceuticals$7.86 billion6.25$2.12 billion$21.4721.36

Regeneron Pharmaceuticals has higher revenue and earnings than Enzon Pharmaceuticals.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Enzon Pharmaceuticals and Regeneron Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Enzon Pharmaceuticals0000N/A
Regeneron Pharmaceuticals061812.80

Regeneron Pharmaceuticals has a consensus price target of $616.8214, suggesting a potential upside of 34.50%. Given Regeneron Pharmaceuticals' higher probable upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Enzon Pharmaceuticals.

Summary

Regeneron Pharmaceuticals beats Enzon Pharmaceuticals on 10 of the 12 factors compared between the two stocks.

Enzon Pharmaceuticals (OTCMKTS:ENZN) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Institutional and Insider Ownership

83.5% of Biogen shares are owned by institutional investors. 0.0% of Enzon Pharmaceuticals shares are owned by insiders. Comparatively, 0.5% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Enzon Pharmaceuticals has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.

Profitability

This table compares Enzon Pharmaceuticals and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Enzon Pharmaceuticals-1,711.94%-20.29%-18.69%
Biogen35.63%51.00%23.54%

Earnings & Valuation

This table compares Enzon Pharmaceuticals and Biogen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enzon Pharmaceuticals$210,000.00217.17$-980,000.00N/AN/A
Biogen$14.38 billion3.00$5.89 billion$33.578.42

Biogen has higher revenue and earnings than Enzon Pharmaceuticals.

Analyst Recommendations

This is a summary of recent recommendations for Enzon Pharmaceuticals and Biogen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Enzon Pharmaceuticals0000N/A
Biogen5151202.22

Biogen has a consensus price target of $304.4667, suggesting a potential upside of 7.68%. Given Biogen's higher probable upside, analysts plainly believe Biogen is more favorable than Enzon Pharmaceuticals.

Summary

Biogen beats Enzon Pharmaceuticals on 9 of the 11 factors compared between the two stocks.

Enzon Pharmaceuticals (OTCMKTS:ENZN) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Institutional and Insider Ownership

87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 0.0% of Enzon Pharmaceuticals shares are owned by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Enzon Pharmaceuticals has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Profitability

This table compares Enzon Pharmaceuticals and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Enzon Pharmaceuticals-1,711.94%-20.29%-18.69%
Alexion Pharmaceuticals16.32%23.16%14.76%

Earnings & Valuation

This table compares Enzon Pharmaceuticals and Alexion Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enzon Pharmaceuticals$210,000.00217.17$-980,000.00N/AN/A
Alexion Pharmaceuticals$4.99 billion6.80$2.40 billion$9.7415.86

Alexion Pharmaceuticals has higher revenue and earnings than Enzon Pharmaceuticals.

Analyst Recommendations

This is a summary of recent recommendations for Enzon Pharmaceuticals and Alexion Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Enzon Pharmaceuticals0000N/A
Alexion Pharmaceuticals017712.36

Alexion Pharmaceuticals has a consensus price target of $153.1250, suggesting a potential downside of 0.88%. Given Alexion Pharmaceuticals' higher probable upside, analysts plainly believe Alexion Pharmaceuticals is more favorable than Enzon Pharmaceuticals.

Summary

Alexion Pharmaceuticals beats Enzon Pharmaceuticals on 11 of the 12 factors compared between the two stocks.


Enzon Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.5$229.99-1.1%$132.83 billion$23.36 billion18.55
Gilead Sciences logo
GILD
Gilead Sciences
2.7$63.71-0.0%$79.86 billion$22.45 billion65.68
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$217.04-0.3%$56.42 billion$4.16 billion27.40Analyst Upgrade
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$458.60-2.1%$49.13 billion$7.86 billion16.76Analyst Report
Biogen logo
BIIB
Biogen
1.9$282.74-1.3%$43.07 billion$14.38 billion9.36
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.9$154.49-1.0%$33.62 billion$4.99 billion36.10
Seagen logo
SGEN
Seagen
1.5$155.02-1.3%$28.08 billion$916.71 million61.03
Exact Sciences logo
EXAS
Exact Sciences
1.6$134.82-2.9%$22.80 billion$876.29 million-61.00Insider Selling
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.6$151.59-1.1%$17.74 billion$219.75 million-19.36Analyst Downgrade
Incyte logo
INCY
Incyte
1.9$80.61-2.0%$17.72 billion$2.16 billion-51.34Insider Buying
Novavax logo
NVAX
Novavax
1.2$239.94-1.4%$15.48 billion$18.66 million-45.97Upcoming Earnings
Analyst Revision
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$83.32-1.4%$15.13 billion$1.70 billion19.07Upcoming Earnings
Insider Selling
News Coverage
Repligen logo
RGEN
Repligen
1.5$215.58-4.2%$11.34 billion$270.24 million262.90News Coverage
Gap Down
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.1$110.61-1.8%$10.39 billion$788.10 million118.94
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.2$56.21-0.3%$7.86 billion$1.12 billion117.10News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.7$173.70-0.8%$7.72 billion$1.45 billion16.43Analyst Report
News Coverage
Exelixis logo
EXEL
Exelixis
1.9$22.66-2.0%$7.07 billion$967.78 million47.21
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$51.45-8.2%$6.96 billion$195.99 million321.56Earnings Announcement
News Coverage
Gap Down
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$98.80-5.4%$5.27 billion$1.11 billion31.77Earnings Announcement
Analyst Upgrade
Analyst Revision
Gap Down
ChemoCentryx logo
CCXI
ChemoCentryx
1.4$67.58-1.7%$4.68 billion$36.13 million-100.87Upcoming Earnings
News Coverage
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.3$80.10-4.4%$4.66 billion$806.43 million-11.35Earnings Announcement
News Coverage
Alkermes logo
ALKS
Alkermes
1.2$19.88-1.2%$3.17 billion$1.17 billion-43.22
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$11.89-0.6%$3.10 billion$182.24 million-10.34Upcoming Earnings
OPKO Health logo
OPK
OPKO Health
1.9$4.58-0.2%$3.07 billion$901.90 million-25.44Earnings Announcement
Insider Buying
Analyst Revision
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$146.34-3.5%$2.35 billion$120.28 million-147.82
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$30.10-3.6%$2.18 billion$638.60 million-11.58Earnings Announcement
Analyst Report
News Coverage
Gap Up
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$11.81-6.1%$2.09 billion$48.83 million-15.54Upcoming Earnings
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$122.80-2.1%$1.86 billionN/A-11.09
ImmunoGen logo
IMGN
ImmunoGen
1.3$9.13-0.4%$1.78 billion$82.27 million-22.27
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$12.52-1.5%$1.77 billion$102.43 million-20.87Gap Down
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.5$9.30-1.9%$1.49 billion$428.41 million13.48Earnings Announcement
Analyst Downgrade
MannKind logo
MNKD
MannKind
1.0$5.98-11.7%$1.39 billion$63.04 million-28.47Upcoming Earnings
Analyst Report
Analyst Revision
News Coverage
Gap Down
Codexis logo
CDXS
Codexis
1.1$22.89-3.1%$1.31 billion$68.46 million-65.40Upcoming Earnings
Gap Down
Innoviva logo
INVA
Innoviva
1.4$11.80-2.8%$1.20 billion$261.02 million6.02
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$20.28-7.8%$1.11 billion$227.19 million56.33
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$27.75-0.1%$1.10 billion$3.57 million-12.44Analyst Report
News Coverage
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$4.90-3.7%$1.05 billion$150,000.00-7.00Upcoming Earnings
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$9.38-3.2%$1.03 billion$35.22 million-6.85Upcoming Earnings
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.7$28.60-1.7%$943.57 million$252 million-2.92Upcoming Earnings
Analyst Downgrade
News Coverage
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$7.75-3.9%$938.57 million$322.07 million-7.38Gap Down
Agenus logo
AGEN
Agenus
1.6$4.18-0.0%$794.82 million$150.05 million-3.83
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$4.37-6.6%$738.45 million$59.29 million-29.13Upcoming Earnings
Analyst Revision
Osiris Therapeutics logo
OSIR
Osiris Therapeutics
0.6$18.99-0.0%$655.69 millionN/A0.00
Geron logo
GERN
Geron
1.4$1.89-1.6%$586.79 million$460,000.00-5.40Analyst Downgrade
Analyst Revision
Molecular Templates logo
MTEM
Molecular Templates
2.0$11.57-2.2%$578.08 million$22.27 million-5.67Analyst Upgrade
Curis logo
CRIS
Curis
1.1$9.93-2.4%$569.94 million$10 million-12.11
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.74-2.4%$545.75 million$109.33 million-2.75Upcoming Earnings
News Coverage
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$6.20-3.1%$530.80 million$143.01 million-1.18Earnings Announcement
Analyst Report
News Coverage
Verastem logo
VSTM
Verastem
1.8$2.57-6.6%$436.32 million$17.46 million-1.82
XOMA logo
XOMA
XOMA
1.6$37.12-3.3%$409.14 million$18.37 million-33.44
This page was last updated on 2/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.